About this trial
This study is a Phase Ib, open label, single arm, adaptive multi-centre clinical study of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma
Patient Profile
The target population for this study are patients with relapsed/refractory multiple myeloma (MM). Patients will have a confirmed diagnosis of MM, with measurable disease as per IMWG criteria, in the second relapse and beyond (third line of therapy and beyond)
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, and University Hospital Galway
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | CPD-DARA |
|---|---|
| Number: | 19-17 |
| Full Title: | Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study) |
| Principal Investigator: | Dr Janusz Krawczyk (Chief Investigator) |
|---|---|
| Type: | In-House |
| Sponsor: | Cancer Trials Ireland |
| Recruitment Started: |
Global: Ireland: Nov 2021 |
| Global Recruitment Target: | |
|---|---|
| Ireland Recruitment Target: | Phase 1: 18 patients Phase 2: 42 patients |